Lobbying registration dated 2026-03-30
Registrant: Bettina Hamelin
Client: Innovative Medicines Canada
Targeted institutions:
Canadian Institutes of Health Research (CIHR)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Global Affairs Canada (GAC)
Canadian International Trade Tribunal (CITT)
Patented Medicine Prices Review Board (PMPRB)
Justice Canada (JC)
Finance Canada (FIN)
House of Commons
National Defence (DND)
Natural Resources Canada (NRCan)
Statistics Canada (StatCan)
Employment and Social Development Canada (ESDC)
Agriculture and Agri-Food Canada (AAFC)
Veterans Affairs Canada (VAC)
National Research Council (NRC)
Canada Revenue Agency (CRA)
Public Health Agency of Canada (PHAC)
Privy Council Office (PCO)
Senate of Canada
Natural Sciences and Engineering Research Council (NSERC)
Health Canada (HC)
Competition Tribunal (CT)
Environment and Climate Change Canada (ECCC)
Prime Minister's Office (PMO)
Fisheries and Oceans Canada (DFO)
Innovation, Science and Economic Development Canada (ISED)
Acts: Patent Act
Food and Drugs Act
Income Tax Act
Government funding received:
Lobbying activity details:
World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry
Federal policies that relate to possible models of pharmacare
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
National Strategy for Drugs for Rare Diseases
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Income Tax Act as it relates to biopharmaceutical products
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
Free trade agreements as they relate to the biopharmaceutical industry
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
World Health Organization (WHO) issues concerning the biopharmaceutical industry